Abstract
Depressive disorders, are not only common but also among the leading causes of disability worldwide. They are associated with increased incidences of various other diseases. It has been shown that in patients with autoimmune diseases, when depression coexists, the quality of life is worse and medical treatment and management is compromised. Depression-like symptoms, such as fatigue and disinterest are also common in inflammatory rheumatic diseases and often associated with poor quality of life. Medical therapy targeting inflammation results in alleviation of these symptoms in many patients. Interestingly, there is cumulating evidence suggesting potential roles of inflammatory cytokines in the pathogenesis of major depression. Effects of some of the biological agents used in rheumatic diseases have been studied on depressive disorders. Results have been controversial and further studies are needed in this area. These findings suggest associations between depression and inflammatory rheumatic diseases and raise the possibility that treatment of one of them might influence the outcome of the other. We have reviewed the current literature on associations between depression and inflammatory rheumatologic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and ankylosing spondylitis.
Keywords: Depression, Inflammation, Rheumatic, Rheumatoid arthritis, Systemic lupus erythematosus, Ankylosing spondylitis, Sjögren's syndrome.
Current Topics in Medicinal Chemistry
Title:Associations between Depressive Disorders and Inflammatory Rheumatic Diseases
Volume: 18 Issue: 16
Author(s): Özkan Varan, Hakan Babaoğlu and Berna Göker*
Affiliation:
- Department of Internal Medicine-Rheumatology, Faculty of Medicine, Gazi University, Ankara,Turkey
Keywords: Depression, Inflammation, Rheumatic, Rheumatoid arthritis, Systemic lupus erythematosus, Ankylosing spondylitis, Sjögren's syndrome.
Abstract: Depressive disorders, are not only common but also among the leading causes of disability worldwide. They are associated with increased incidences of various other diseases. It has been shown that in patients with autoimmune diseases, when depression coexists, the quality of life is worse and medical treatment and management is compromised. Depression-like symptoms, such as fatigue and disinterest are also common in inflammatory rheumatic diseases and often associated with poor quality of life. Medical therapy targeting inflammation results in alleviation of these symptoms in many patients. Interestingly, there is cumulating evidence suggesting potential roles of inflammatory cytokines in the pathogenesis of major depression. Effects of some of the biological agents used in rheumatic diseases have been studied on depressive disorders. Results have been controversial and further studies are needed in this area. These findings suggest associations between depression and inflammatory rheumatic diseases and raise the possibility that treatment of one of them might influence the outcome of the other. We have reviewed the current literature on associations between depression and inflammatory rheumatologic diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Sjögren’s syndrome and ankylosing spondylitis.
Export Options
About this article
Cite this article as:
Varan Özkan, Babaoğlu Hakan and Göker Berna *, Associations between Depressive Disorders and Inflammatory Rheumatic Diseases, Current Topics in Medicinal Chemistry 2018; 18 (16) . https://dx.doi.org/10.2174/1568026618666180516100805
DOI https://dx.doi.org/10.2174/1568026618666180516100805 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-IL-12/23 in Crohn's Disease: Bench and Bedside
Current Drug Targets Biologics: An Update and Challenge of Their Pharmacokinetics
Current Drug Metabolism The Importance of Guidelines in the Development and Application of Probiotics
Current Pharmaceutical Design Recognition of Classical and Heavy Chain Forms of HLA-B27 by Leukocyte Receptors
Current Molecular Medicine Anti-Tumor Necrosis Factor-α Therapy in Undifferentiated Spondyloarthritis (USpA)
Current Rheumatology Reviews Silencing of Tumor Necrosis Factor Receptor-1 in Human Lung Microvascular Endothelial Cells Using Particle Platforms for siRNA Delivery
Current Drug Targets IL-1 as a target in inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Quantitative Structure Activity Relationship (QSAR) Analysis of Substituted 4-Oxothiazolidines and 5-Arylidines as Lipoxygenase Inhibitors
Mini-Reviews in Medicinal Chemistry The Characteristic of Histopathology in Spondyloarthropathy
Current Rheumatology Reviews Which Biomarker is Useful to Evaluate as a Treatment Outcome in Spondyloarthritis?
Current Rheumatology Reviews Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Amyloidosis and Auto-Inflammatory Syndromes
Current Drug Targets - Inflammation & Allergy Small Molecules as Anti-TNF Drugs
Current Medicinal Chemistry A Proposed Serum Calprotectin IgG Cut-Off Level for Diagnosing Inflammatory Arthritis
Current Rheumatology Reviews Antifungal Therapy of Aspergillosis of the Central Nervous System and Aspergillus Endophthalmitis
Current Pharmaceutical Design All in the Family: The TNF-TNFR Superfamily in the Pathogenesis and Treatment of Rheumatoid Arthritis and other Inflammatory Diseases
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents JAK/STAT Signal Transduction: Promising Attractive Targets for Immune, Inflammatory and Hematopoietic Diseases
Current Drug Targets The Role of HLA-B27 in the Pathogenesis of Ankylosing Spondylitis
Current Rheumatology Reviews Risk-Benefit Perspectives in COX-2 Blockade
Current Drug Safety Spondyloarthritis in Asian Countries – An Overview
Current Rheumatology Reviews